Regarding the Feb. 26 editorial “A new superbug threat”:

While the editorial shone a much-needed spotlight on the growing threat of antimicrobial resistance and highlighted a commercial environment that does not commensurately value the development of potentially lifesaving antibiotics, it overlooked the urgent need to pass legislation that supports the discovery of new antibiotics and addresses the failure of the marketplace to incentivize investment in the development of antimicrobials.

Fortunately, bipartisan support exists to make progress. Congress passed the Generating Antibiotic Incentives Now Act in 2012 and more recently authorized the limited-population antibacterial and antifungal drug pathway initiative, as part of the 21st Century Cures Act.

Reforming the broken hospital reimbursement system along with providing tax credits to incentivize development of novel antimicrobials is necessary. A “market entry award” program to de-link revenue for a newly approved drug from its commercial sales is intriguing. Pending legislation holds promise, but it is unclear when or if any will advance in the current political environment.

Cooperation among academia, industry and bipartisan congressional support is imperative to stimulate innovative antimicrobials. Without adequately addressing the stymied market, necessary innovation for our next “miracle drugs” will come to a rapid stop.

Jeffrey Stein, Del Mar, Calif.

The writer is president and chief executive of ­Cidara Therapeutics and chairman of the
Antimicrobials Working Group.